Gregory K. Palm
Director/Board Member chez Olatec Therapeutics LLC
Profil
Gregory K.
Palm is currently a Director at Olatec Therapeutics LLC since 2021.
Previously, he worked as Secretary, Executive VP & General Counsel at The Goldman Sachs Group, Inc. from 2011 to 2018.
He completed his undergraduate degree at Massachusetts Institute of Technology and his graduate and MBA degrees at Harvard Business School.
Postes actifs de Gregory K. Palm
| Sociétés | Poste | Début |
|---|---|---|
Olatec Therapeutics LLC
 Olatec Therapeutics LLC Pharmaceuticals: MajorHealth Technology Olatec Therapeutics LLC is a privately held biopharmaceutical company based in the United States. The American company is in the clinical stage of developing a platform of oral NLRP3 inhibitors to treat and prevent a broad spectrum of acute and chronic inflammatory diseases mediated by IL-1. Olatec's proprietary compounds include approximately 60 analogues being screened as viable drug candidates, and the company has over 140 patents granted covering its compounds. The company's drug development team is comprised of experienced management and international experts in translational medicine with unparalleled expertise in inflammation and immunology. Olatec is conducting clinical trials in the FDA and EMA. The company was founded by Damaris B. Skouras, who has been the CEO since incorporation. | Director/Board Member | 29/07/2021 |
Anciens postes connus de Gregory K. Palm
| Sociétés | Poste | Fin |
|---|---|---|
| THE GOLDMAN SACHS GROUP, INC. | General Counsel | - |
Formation de Gregory K. Palm
| Massachusetts Institute of Technology | Undergraduate Degree |
| Harvard Business School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| THE GOLDMAN SACHS GROUP, INC. | Finance |
| Entreprise privées | 1 |
|---|---|
Olatec Therapeutics LLC
Olatec Therapeutics LLC Pharmaceuticals: MajorHealth Technology Olatec Therapeutics LLC is a privately held biopharmaceutical company based in the United States. The American company is in the clinical stage of developing a platform of oral NLRP3 inhibitors to treat and prevent a broad spectrum of acute and chronic inflammatory diseases mediated by IL-1. Olatec's proprietary compounds include approximately 60 analogues being screened as viable drug candidates, and the company has over 140 patents granted covering its compounds. The company's drug development team is comprised of experienced management and international experts in translational medicine with unparalleled expertise in inflammation and immunology. Olatec is conducting clinical trials in the FDA and EMA. The company was founded by Damaris B. Skouras, who has been the CEO since incorporation. | Health Technology |
